DEVELOPMENT AND ASSESSMENT OF A GEL CONTAINING MOXIFLOXACIN HYDROCHLORIDE ENCAPSULATED IN CUBOSOMES FOR TARGETED DELIVERY TO THE EYE

Abstract

The objective of this study was to create and assess a sustained-release cubogel formulation of moxifloxacin hydrochloride (MX) for the treatment of conjunctivitis. A cubosome carrying the antibiotic MX was created utilising a top-down method by utilising different quantities of glycerol monooleate and poloxamer 407. In addition, MX cubogels were created by scattering optimised cubosomes in a cold in-situ gelling method. According to Higuchi's release kinetic model, formulations MA4, MA8, MA11, and MA14 released 95.84%, 95.77%, 97.45%, and 97.68% of MX after a duration of 12 hours. The in-vitro corneal permeation investigation shown that the goat cornea absorbed 81% more MX cubogel compared to traditional formulations. Based on the findings of antibacterial and histological tests, it can be concluded that the chosen formulations are suitable for safe administration in the eyes. The study determined that MX cubogel exhibits enhanced permeability and prolonged release properties, making it a potential substitute for traditional eye drops.